Samuel Wong is a Visiting Professor in the Physics Department at Stanford University, affiliated with the School of Humanities and Sciences. His research focuses on radiomics, machine learning applications in pediatric neuro-oncology, and medical imaging diagnostics. He has contributed to multinational studies on posterior fossa tumors and neonatal critical care protocols. Notably, he developed radiomic phenotyping techniques to differentiate pediatric brain tumors like ATRT from medulloblastoma. His work bridges computational methods with clinical practice, emphasizing translational medicine. Recent publications (2021-2022) highlight advancements in diagnostic algorithms for pediatric tumors, neonatal transport intubation protocols, and cardiorespiratory management of extremely preterm infants. A 2012 paper explored historical financial market structures at the NYSE. His collaborations span institutions globally, reflecting a commitment to interdisciplinary research. No specific awards or grants are listed, though his involvement in high-impact clinical studies suggests recognition in medical physics and oncology domains. He advises no listed students but collaborates with research teams in physics and biomedical engineering laboratories at Stanford.
Professor Marcel Nold is a consultant neonatologist at Monash Newborn, Monash Health, Professor of Pediatric Immunology in the Department of Paediatrics at Monash University, and a clinician-scientist at the Hudson Institute of Medical Research. His work bridges clinical practice and cutting-edge research in neonatal inflammation and immunology. His research focuses on cytokine biology, particularly the role of IL-37 in inflammation, with applications in preterm infant diseases such as bronchopulmonary dysplasia and necrotizing enterocolitis. He leads the Inflammation in Neonatal Diseases Research Group, aiming to develop interventional immunology strategies for cardiopulmonary and intestinal conditions in neonates. Recent publications (2023–2025) highlight continued leadership in neonatal immunology, vaccine safety, cytokine signaling, and inflammatory disease mechanisms. His work spans basic discovery, translational development, and clinical application, including collaborations with pharmaceutical partners and the development of novel biologics. Discovery of IL-37's anti-inflammatory function (2010) Identification of IL-37 receptor and structural determinants (2015) Development of modified IL-37 as immunotherapeutic Active research in preterm cardiovascular and intestinal inflammation Prof Nold is a co-founder and Clinical Scientific Officer of a start-up company focused on cytokine therapies, supported by life science venture capital. He holds multiple patents related to cytokine biology and has been a Chief Investigator on numerous funded projects, including NHMRC and internal university grants. His research group actively contributes to advancing neonatal care through innovative science. He is affiliated with Monash University’s Faculty of Medicine, Nursing and Health Sciences and the Hudson Institute of Medical Research, where he conducts both academic and translational research. His work contributes to UN Sustainable Development Goals related to good health and well-being.
Namasivayam Ambalavanan, M.D. is a Professor and Co-Division Director of Neonatology at the University of Alabama at Birmingham School of Medicine. He holds the Virginia Walker Jones Endowed Chair in Neonatology and serves as Program Director for the Neonatal-Perinatal Fellowship Program. Additionally, he is Director of the Sergio B. Stagno Research Endowment and Director of Neonatal Research. Medical School: Jawaharlal Institute of Post Graduate Medical Education and Research (JIPMER), Pondicherry, India (MBBS) Internship: JIPMER Pondicherry, India Residency: Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India (MD Pediatrics) Fellowship: University of Alabama at Birmingham (Neonatology) Dr. Ambalavanan's research focuses on biomarkers and prediction of outcomes in premature infants, with particular expertise in genomic analyses in bronchopulmonary dysplasia (BPD) and prediction models for extremely premature outcomes. His work spans basic science, translational research, and clinical investigations, with over 300 publications to date (90 as first or senior author). As Director of the Translational Research in Normal and Disordered Development (TReNDD) Program, he leads a comprehensive research program addressing neonatal lung development and injury. Analysis of his recent publications (2025) reveals a strong emphasis on neonatal respiratory outcomes, particularly bronchopulmonary dysplasia and pulmonary hypertension in preterm infants. His research increasingly incorporates genomic, multiomic, and biomarker approaches to understand disease mechanisms and improve prediction models. A significant portion of his current work focuses on the impact of prenatal opioid exposure on neonatal outcomes, reflecting his leadership in the NIH HEAL initiative. His clinical trials work spans respiratory support strategies, caffeine therapy, and fluid management protocols for vulnerable neonatal populations. Virginia Walker Jones Endowed Chair in Neonatology Principal Investigator for one of five NIH Pre-VENT research centers Principal Investigator for the NIH HEAL project on outcomes of infants with opioid exposure Dr. Ambalavanan has demonstrated exceptional mentorship, having trained multiple junior faculty including three with K08 awards, one with R01 funding, one with AHA SDG, and one with industry funding. He leads a basic science laboratory while managing single-center and multicenter observational and interventional clinical studies. The UAB neonatal program serves as a regional perinatal center with approximately 350 very low birth weight (VLBW) infant births per year (200+ extremely low birth weight infants/year) and participates in the NICHD Neonatal Research Network (where he serves as alternate center PI), the Global Network, and the MFMU Network. Within the Neonatal Research Network, he chairs the Budesonide in Babies subcommittee, co-chairs the Genomics subcommittee, and serves on the Late Hypothermia and MoCHA subcommittees.
Associate Professor Atul Malhotra is a senior neonatologist at Monash Newborn, Monash Children's Hospital, and a research academic in the Department of Paediatrics, Monash University. He is the co-director of the Newborn Cell Therapies Group at the School of Clinical Sciences at Monash Health and leads multiple active research projects. He is the current recipient of an NHMRC Emerging Leadership Fellowship and has secured over $20 million in research funding. Education: PhD in Basic Science, Monash University (2014–2019) FRACP in Paediatrics-Neonatal-Perinatal Medicine, Royal Australasian College of Physicians (2005–2009) DNB in Paediatrics, National Board of Examinations (2002) MD in Paediatrics, University of Delhi (1999–2002) MBBS in Medicine, University of Delhi (1993–1997) His research focuses on improving respiratory and neurological outcomes in high-risk infants. He is passionate about neurodevelopment after high-risk birth and leads the Early Neurodevelopment Clinic at Monash Children's Hospital. His work spans clinical trials, evidence-based neonatology, fetal growth restriction, and regenerative medicine. He also explores medical device innovation and AI in newborn monitoring through collaboration with Monash's Faculty of Engineering. His recent publications highlight pioneering work in cord blood cell therapy, perinatal brain injury, pandemic impacts on preterm birth, and vaccine safety in preterm infants. These reflect a strong trend in translational neonatal research, integrating clinical practice with laboratory science and public health. Scientific Awards and Honors: NHMRC Emerging Leadership Fellowship ANZNN Neonatal Research Award (2019) Best of Stem Cells Translational Medicine 2018 (2019) Cerebral Palsy Alliance Emerging Researcher (2020) Eric Burnard Fellowship (2018) Best Poster, Monash Health Research Week (2013) He has been instrumental in securing major research grants, including leadership of the trial Cell Therapies for Newborn Infants: Translating Promise to Benefits , and serves as Principal Investigator on multiple active projects. He has advised on national policy through roles in the Royal Australasian College of Physicians and is actively mentoring the next generation of researchers, accepting PhD students via SupervisorConnect. He is the co-founder of the global interprofessional education initiative ONE-Sim Education and served as inaugural Co-Chair of Monash Children's Hospital's Simulation Centre. He leads the Biomedical Signal Processing Lab in collaboration with Monash Engineering, aiming to improve neonatal monitoring. He is also co-director of the Newborn Cell Therapies Group , advancing regenerative therapies from bench to bedside. His work contributes to UN Sustainable Development Goals in health and education.
Stephanie Merhar, MD, is an Associate Professor of Pediatrics at the University of Cincinnati and attending neonatologist at Cincinnati Children’s Hospital Medical Center. Her clinical and research portfolio centers on neonatal neurology, advanced neuro-imaging in the NICU, and the developmental consequences of extremely preterm birth and prenatal opioid exposure. Education & Training: While specific degree dates are not listed, Dr Merhar’s extensive peer-reviewed output and faculty rank indicate subspecialty fellowship training in Neonatal–Perinatal Medicine following pediatric residency. Research Interests: Neonatal brain development and injury in extremely preterm infants Functional and structural connectivity MRI applied to high-risk neonates Neonatal opioid withdrawal syndrome (NOWS) – pathophysiology, care pathways, and long-term neurodevelopment Advanced MRI techniques (diffusion tensor imaging, ultrashort echo-time pulmonary MRI, on-site NICU scanners) Early biomarkers of cerebral palsy and cognitive/ language impairment Feeding intolerance and post-hemorrhagic hydrocephalus biomarkers Publication Trends: Between 2021-2023 Dr Merhar has led or co-authored >25 high-impact papers. Work clusters into three major domains: (1) prospective multicenter trials of NOWS management (Eat-Sleep-Console, OBOE, ESC-NOW), (2) longitudinal imaging studies correlating neonatal MRI metrics with 2-year neurodevelopmental outcomes, and (3) technical innovations enabling safe, quiet, on-site MRI of unstable neonates. These publications appear in The New England Journal of Medicine , JAMA , Pediatric Research , NeuroImage: Clinical , and American Journal of Neuroradiology . Scientific Awards & Honors: None explicitly listed in the provided text. Grants & Collaborative Networks: Dr Merhar is an active investigator within the NICHD Neonatal Research Network, leading neuroimaging components of several multi-site trials. She collaborates closely with the Outcomes of Babies with Opioid Exposure (OBOE) consortium and serves as site PI for Cincinnati Children’s in the ESC-NOW stepped-wedge RCT. Laboratories & Teams: She conducts imaging research within the neonatal neuro-imaging program at Cincinnati Children’s, utilizing the on-site 1.5-T small-footprint MRI scanner and the hospital’s 3-T research systems. Her team includes MRI physicists, neonatal neuro-radiologists, developmental neuropsychologists and biostatisticians.
Anne Mette Plomgaard serves as a Clinical Associate Professor in the Department of Clinical Medicine within the Faculty of Health and Medical Sciences at the University of Copenhagen, specializing in Pediatrics with a focus on neonatal care. Her research expertise spans: Neurodevelopmental outcomes in preterm infants Cerebral oximetry monitoring applications EEG-based neurophysiological assessment Clinical trial design for neonatal intensive care Current work centers on the SafeBoosC international research consortium, analyzing cerebral oxygenation and brain activity patterns to predict long-term disability in extremely preterm infants. Her 2024 publication established EEG-burst sharpness as a biomarker for 2-year neurodevelopmental outcomes, while the 2023 study protocol outlines methodology for extended follow-up of oximetry-guided interventions. She maintains active collaboration across European neonatal research networks, contributing to evidence-based protocols for high-risk infant care through multi-center clinical trials.
Kristine Hermansen Grunewaldt serves as an Associate Professor in the Department of Clinical and Molecular Medicine at the Norwegian University of Science and Technology (NTNU), Faculty of Medicine. Her research is centered at Kvinne-barnsenteret (Women and Children's Hospital) on Øya campus, focusing on high-risk infant populations and neurodevelopmental outcomes. Her primary research interests include neonatal care, preterm infant development, neurodevelopmental trajectories in very low birth weight (VLBW) children, respiratory support interventions, and cognitive training methodologies. She employs longitudinal study designs with multimodal assessments including neuroimaging, motor function evaluations, and cognitive testing to understand developmental pathways from infancy through school age. Analysis of her 15 most recent publications reveals a consistent focus on preterm infant outcomes, with particular emphasis on neurodevelopmental consequences of prematurity, respiratory interventions in neonates, and cognitive interventions for VLBW children. Her work spans clinical trials, neuroimaging studies, and longitudinal cohort analyses, demonstrating strong methodological diversity while maintaining thematic coherence around high-risk infant development. Her academic contributions include numerous publications in high-impact journals such as JAMA Network Open, Pediatrics, and Developmental Medicine & Child Neurology, with recent work increasingly focusing on randomized clinical trials and advanced neuroimaging techniques to elucidate mechanisms underlying developmental outcomes. Dr. Grunewaldt actively collaborates with multidisciplinary teams across Norwegian institutions, with frequent co-authorship patterns indicating strong research networks in neonatology, pediatric neurology, and developmental medicine. Her work demonstrates consistent translational focus, bridging clinical observations with mechanistic investigations to inform early intervention strategies for at-risk infants.
Dr. Toby Yanowitz is an Associate Professor of Pediatrics at the University of Pittsburgh School of Medicine and Director of Clinical Research at UPMC Children's Hospital and Magee Women's Hospital. She holds an M.D. from Albert Einstein College of Medicine (1991) and an M.S. in Epidemiology from the University of Pittsburgh (2008). Her clinical expertise includes neonatal neurocritical care and perinatal epidemiology. Her research focuses on: Neurologic outcomes in preterm/term infants Necrotizing enterocolitis prevention Hemodynamic disturbances in neonatal brain injury Dr. Yanowitz directs neonatal databases for the Vermont Oxford Network and Children’s Hospitals Consortium. She has served as site-PI for landmark trials including the Cool Cap trial (therapeutic hypothermia for HIE) and HEAL study. She mentors trainees in clinical research on neonatal brain development and transitional hemodynamics. Honors include the Perinatal Research Society NIH Young Investigator Award and teaching awards for neonatal fellowship mentoring. Recent publications (2019-2024) center on cord management strategies, neuroprotective therapies, and surgical outcomes in NEC.
Megan Spencer-Smith is a Senior Lecturer in Developmental Psychology and Director of Undergraduate Education (on campus) at the School of Psychological Sciences, Monash University, Melbourne, Australia. Her research focuses on cognitive training in pediatric populations and developmental outcomes in children with agenesis of the corpus callosum. She holds a PhD from the University of Melbourne (2008) and has held postdoctoral fellowships at institutions such as the Karolinska Institute and Murdoch Childrens Research Institute. Education: PhD in Child Neuropsychology, University of Melbourne (2008) Visiting Research Fellowships: Hospital for Sick Children (Toronto, Canada), Inselspital (Bern, Switzerland), and Karolinska Institute (Sweden) Research interests revolve around: Cognitive training efficacy and sustained benefits in children Developmental differences in cognitive, academic, and behavioral functions in typically developing children and those with agenesis of the corpus callosum Notable awards include the Harold Mitchell Travelling Fellowship (2011) , Monash University’s Jenny Redman Prize (2016) , and multiple competitive fellowships. She contributes to global efforts aligned with UN Sustainable Development Goals, particularly in health and education equity. Advising and grants: She supervises PhD students and leads projects such as Understanding ADHD in Indigenous Australian children and Digital Training Technology for Cognitive Skills . Her lab at Monash investigates neurodevelopmental outcomes and intervention strategies for pediatric populations.
Professor Suzanne Miller is a leading researcher and academic at Monash University, where she serves as Director of The Ritchie Centre and leads the Neurodevelopment Theme. She is affiliated with the Faculty of Medicine, Nursing and Health Sciences and the Department of Obstetrics & Gynaecology at Monash Health. A National Health and Medical Research Council (NHMRC) Australia Level 2 Investigator (2023–2027), she holds the academic rank of Professor (Research) and is actively engaged in translational research in perinatal and neonatal brain injury. Her educational background includes a PhD and BSc (Hons) in Medicine, Nursing and Health Sciences, both from Monash University, completed in 1999 and 1992, respectively. Suzanne Miller’s research focuses on neurodevelopmental physiology , particularly the mechanisms underlying perinatal brain injury in conditions such as fetal growth restriction, preterm birth, in utero infection, and birth asphyxia. Her work integrates preclinical models and clinical studies to develop targeted neuroprotective therapies. She combines experimental physiology with advanced neuroimaging and cell-based interventions, including umbilical cord blood therapies. The most recent articles highlight a strong trend in translational neonatal neuroscience , with studies on cord blood cell therapy, early neurodevelopmental assessment, hippocampal development, and injury detection in preterm and growth-restricted infants. Her research spans both animal models and human clinical trials, reflecting a comprehensive bench-to-bedside approach. She has been recognized with the Exceptional Achievement Award (2018) and plays a significant role in academic leadership and scientific dissemination: Editor-in-Chief, Frontiers in Physiology (2018–2019) Editor-in-Chief, Frontiers in Endocrinology (2018–2019) Editor-in-Chief, The Journal of Physiology (from June 2018) Organiser, European Workshop on Fetal Growth Restriction (2018) Miller leads or co-leads several major research grants, including the NHMRC-funded PROTECT Me study on melatonin supplementation and the Cerebral Palsy SYNERGY Network . She is also a founding member of the NHMRC’s Women in Health Science Committee , advocating for gender equity in medical research. Her work contributes to UN Sustainable Development Goals, particularly in health and well-being. She is actively involved in mentoring and research team leadership at The Ritchie Centre, a collaborative hub between Monash University and Hudson Institute of Medical Research, focusing on reproductive, fetal, and neonatal health.
Jaakko Hollmen serves as a Senior University Lecturer in the Department of Computer Science at Aalto University, affiliated with the Helsinki Institute for Information Technology (HIIT) and the Computer Science Lecturers research group. His interdisciplinary work bridges machine learning with critical applications in healthcare, transportation systems, and environmental science. His research focuses on advanced machine learning methodologies including Bayesian optimization, random forests, and principal component analysis. Key application areas span neonatal healthcare (mortality prediction, brain injury analysis), transportation modeling (activity-based model calibration), and environmental data science (weather-crop relationships, drug-environment interactions). His approach emphasizes practical implementations of complex algorithms for real-world problems. Hollmen's recent publications (2018-2023) reveal a consistent trajectory in developing machine learning solutions for high-dimensional data challenges, with increasing emphasis on medical applications. His work demonstrates strong cross-domain collaboration, particularly with medical researchers at Helsinki University Hospital. His notable recognition includes: Best paper finalist and runner-up award (Computer Track) at the first IEEE Life Sciences Conference (LSC) for research on predicting complications in very low birth weight infants (2017) As a core member of HIIT, Hollmen contributes to Finland's national information technology research infrastructure while maintaining active collaborations with medical and agricultural research groups. His current projects focus on optimizing transportation models and advancing clinical prediction systems through novel machine learning techniques.
Lina Chalak, M.D., M.S.C.S., serves as a Professor in the dual appointments of the Department of Pediatrics and Department of Psychiatry at UT Southwestern Medical Center's School of Medicine. She founded and directs both the Neurointensive Care program and the Fetal Neonatal Neurology Fellowship Program. Board certified in general pediatrics and neonatal-perinatal medicine, Dr. Chalak has been a faculty member at UT Southwestern since 2008. Her primary research focuses on neonatal brain injury mechanisms, particularly asphyxia, hypothermia, and neonatal encephalopathy. She pioneered the 'Neurovascular bundle' for real-time evaluation of cerebral blood flow and neuronal activity coupling in asphyxiated newborns. Her federally funded research examines cerebrovascular autoregulation, neuronal biomarkers in HIE, and inflammatory pathways in neuronal injury. Current projects include the PRIME mild asphyxia collaborative study and multi-organ dysfunction analysis across the neonatal encephalopathy spectrum. Analysis of Dr. Chalak's 15 most recent publications reveals dominant research themes in therapeutic hypothermia optimization (particularly for preterm infants), placental pathology's role in neurologic outcomes, multi-organ involvement in encephalopathy, and advanced neuromonitoring techniques. Her work spans clinical trials (e.g., SafeBoosC-III, HEAL), epidemiological studies in safety-net hospitals, and mechanistic investigations of inflammatory responses. Serves on NIH review panels Executive Council member of the American Pediatric Society (APS) Society for Pediatric Research (SPR) leadership Chair of consensus definition initiatives for neonatal encephalopathy Dr. Chalak leads a multi-science research team integrating physiologists and biomedical engineers to develop novel neurovascular assessment tools. Her work bridges clinical care with translational research, emphasizing real-time physiological monitoring to improve neurodevelopmental outcomes. Future directions include expanding mild HIE treatment protocols and refining biomarker-based outcome prediction models.
Jean A Frazier, MD , is a Professor at UMass Chan Medical School, holding the Robert M. and Shirley S. Siff Chair in Autism. She is affiliated with multiple departments including Psychiatry and Behavioral Sciences, Pediatrics, Neuroscience, and Translational Science across the T.H. Chan School of Medicine and Morningside Graduate School of Biomedical Sciences. She serves as Vice Chair and Director of the Division of Child and Adolescent Psychiatry and co-directs the Child and Adolescent Neurodevelopment Initiative (CANDI). B.A. in Music, Wellesley College (1982) MD, Dartmouth Medical School (1987) Residency and fellowship training in psychiatry and child psychiatry at Tufts-New England Medical Center, Brown University, and the National Institute of Mental Health Dr. Frazier leads a multidisciplinary research program focused on neurodevelopmental disorders such as autism, early-onset bipolar disorder, and schizophrenia. Her work emphasizes the overlap in symptoms, genetics, and neuroimaging findings across these conditions to identify diagnostic biomarkers and improve clinical interventions. CANDI conducts research in genetics, neuroimaging (e.g., MRI), and intervention studies, often in collaboration with national and local investigators. Her recent publications reflect a strong emphasis on long-term outcomes in preterm infants, mental health during the pandemic, autism phenotypes, and psychopharmacology. She investigates emotional dysregulation, neuroimaging biomarkers, and social cognition, with a growing interest in health disparities and access to care. Dr. Frazier has received multiple honors, including: National Alliance for the Mentally Ill Exemplary Psychiatrist Award Massachusetts Psychiatric Society Outstanding Psychiatrist Award for Research Distinguished Fellow of the American Psychiatric Association Best Doctors in America New England Educational Institute’s Outstanding Educator Award She has held significant professional service roles, including editorial positions at the Harvard Review of Psychiatry , membership on NIH review panels, and advisory roles for national mental health organizations. She mentors numerous trainees and collaborates widely on grants and research initiatives. Dr. Frazier is actively involved in national conversations on pediatric mental health crises, research equity, and antiracist practices in psychiatry. She leads or contributes to major research initiatives such as CANDI, the Autism Consortium in Boston, and multi-site studies on early-onset bipolar disorder and schizophrenia. Her lab focuses on integrating clinical, neuroimaging, and genetic data to advance precision psychiatry in youth.
Professor Shakoor Hajat is a Professor of Global Environmental Health at the London School of Hygiene & Tropical Medicine , affiliated with the Department of Public Health, Environments and Society within the Faculty of Public Health and Policy. He serves as Director of the NIHR Health Protection Research Unit on Environmental Change and Health and contributes to the Centre on Climate Change and Planetary Health. Director, NIHR Health Protection Research Unit on Environmental Change and Health Committee Member, Centre on Climate Change and Planetary Health Editorial Board Member, International Journal of Environmental Research and Public Health Member, Global Climate-Homelessness Network Research Interests : Professor Hajat focuses on Climate Change , Planetary Health , and Environmental Health , particularly examining heat-related mortality, climate change impacts on vulnerable populations, and temperature-related health burdens. His recent work explores: Heat-related health risks for homeless populations Climate change effects on maternal and child health Neurological disease implications Temperature-mortality associations in Europe and Brazil Climate adaptation frameworks Teaching & Supervision : He directs the intensive MSc Public Health programme , organizes the Basic Statistics for PHP module , and lectures on Environmental Epidemiology. He has contributed to developing the new MSc Climate Change and Planetary Health programme and currently supervises three research degree students. Key Grants : NIHR Health Protection Research Unit on Climate Change and Health Security (2025-2030) HEARTH: National Hub on Net Zero Health and Extreme Heat (2025-2030) Developing solutions for temperature-related health impacts in the UK (2024-2028)
Dr Tamara Yawno-Fegan is a Senior Research Fellow in the Department of Paediatrics at Monash University, affiliated with Monash Health. Her research is centered on understanding perinatal and neonatal brain injury, with a strong focus on neurosteroids, stem cell therapies, and regenerative medicine approaches to prevent cerebral palsy and improve neonatal outcomes. Research Interests: Dr Yawno-Fegan’s work spans neurosteroid biology in fetal brain development, the pathophysiology of perinatal brain injury, and innovative therapeutic strategies such as ganaxolone for neonatal seizures and placental or cord blood-derived cell therapies. Her research group investigates both experimental models and clinical applications, aiming to bridge the gap between basic science and clinical practice. Recent Research Trends: Analysis of her recent publications reveals a consistent trajectory toward translational neonatal neuroscience, particularly in evaluating novel therapeutics like ganaxolone (GaINS trial), melatonin, and cell-free regenerative approaches. Her work increasingly emphasizes timing, safety, and mechanistic understanding in preterm and growth-restricted infants, often using large animal models and leading to phase I clinical trials. Scientific Awards: Fellowship from the Royal Australian and New Zealand College of Obstetrics and Gynaecologists (stem cell therapies) Career Development Grant from the Cerebral Palsy Alliance of Australia Grants and Advising: Dr Yawno-Fegan has been a Chief Investigator on multiple competitive grants, including NHMRC and Cerebral Palsy Alliance-funded projects. She collaborates extensively with clinical and academic leaders in neonatology and neurology. While no formal students are listed, she likely supervises research trainees within her collaborative teams. Labs and Teams: She is embedded in a multidisciplinary research environment at Monash, collaborating with experts in obstetrics, neonatology, pharmacology, and regenerative medicine. Her work is integral to initiatives such as the GaINS trial and studies on placental cell therapies, often conducted in partnership with Hudson Institute of Medical Research and Monash Newborn.
